

one-north (Biopolis / Fusionopolis)

City Innovation Library · Good practice · Singapore

Quality score: 62/100

Evidence strength: Moderate

Summary

Since its 2001 launch, Singapore's 200-hectare one-north estate — Biopolis and Fusionopolis — has grown to 400+ companies and 50,000+ knowledge workers around A*STAR's research institutes, though early biopharma spinoff commercialization lagged its manufacturing growth.

Key dimensions

Dimension	Score
Evidence of impact / measured results	2/3
Transferability / demonstrated replication	1/3
Scalability	3/3
Sustainability / continuity	2/3
Innovation	2/3
Inclusiveness / equity	0/3
Multi-stakeholder collaboration	3/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-15

[JTC Corporation \(Singapore government statutory board\), with A*STAR public research institutes](#) — accessed 2026-07-15

[BioSpace — Singapore's Biopolis: a success story?](#) — accessed 2026-07-15

[PMC/NIH — Biopolis academic analysis](#) — accessed 2026-07-15

Cite this — Evidoria. *one-north (Biopolis / Fusionopolis)*. Persistent ID: 0e70a1a3-35a0-4076-9988-7876d0421e27.